In type 2 diabetes, dipeptidyl peptidase-4 inhibitors do not increase pancreatitis

被引：1
|
作者：
Morey-Vargas, Oscar L. [1 ]
Montori, Victor M. [1 ]
机构：
[1] Mayo Clin, Rochester, MN 55905 USA
来源：
ANNALS OF INTERNAL MEDICINE | 2014年 / 160卷 / 02期
关键词：
THERAPIES;
D O I：
10.7326/0003-4819-160-2-201401210-02008
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Dipeptidyl peptidase-4 inhibitors and sulfonylureas for type 2 diabetes: Friend or foe?
    Yabe, Daisuke
    Seino, Yutaka
    JOURNAL OF DIABETES INVESTIGATION, 2014, 5 (05) : 475 - 477
  • [22] Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus
    不详
    JOURNAL OF DIABETES, 2009, 1 (01) : 6 - 7
  • [23] Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy - focus on alogliptin
    Capuano, Annalisa
    Sportiello, Liberata
    Maiorino, Maria Ida
    Rossi, Francesco
    Giugliano, Dario
    Esposito, Katherine
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2013, 7 : 989 - 1001
  • [24] Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes
    Koska, Juraj
    Sands, Michelle
    Burciu, Camelia
    Reaven, Peter
    DIABETES & VASCULAR DISEASE RESEARCH, 2015, 12 (03): : 154 - 163
  • [25] Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus
    Richter, B.
    Bandeira-Echtler, E.
    Bergerhoff, K.
    Lerch, C. L.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2008, (02):
  • [26] Dipeptidyl peptidase-4 inhibitors increase risk of IBD
    Reactions Weekly, 2018, 1696 (1) : 5 - 5
  • [27] Dipeptidyl Peptidase-4 Inhibitors Do Not Increase the Risk of Cardiovascular Events in Type 2 Diabetes: A Population-Based Cohort Study
    Kim, Seoyoung C.
    Glynn, Robert
    Liu, Jun
    Everett, Brendan M.
    Goldfine, Allison B.
    ENDOCRINE REVIEWS, 2014, 35 (03)
  • [28] Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture
    Driessen, Johanna H. M.
    van Onzenoort, Hein A. W.
    Henry, Ronald M. A.
    Lalmohamed, Arief
    van den Bergh, Joop P.
    Neef, Cees
    Leufkens, Hubert G. M.
    de Vries, Frank
    BONE, 2014, 68 : 124 - 130
  • [29] Pharmacogenetics of dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes mellitus: A review
    Samoilova, Iuliia G.
    Vaizova, Olga E.
    Stankova, Anastasia E.
    Matveeva, Mariia, V
    Podchinenova, Daria, V
    Kudlay, Dmitry A.
    Borozinets, Anastasiia A.
    Filippova, Tatyana A.
    Grishkevich, Ivan R.
    Partala, Anastasia, V
    Gerasimova, Diana A.
    TERAPEVTICHESKII ARKHIV, 2024, 96 (01) : 63 - 67
  • [30] Renoprotective Effect of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus
    Esaki, Hiroki
    Tachi, Tomoya
    Goto, Chitoshi
    Sugita, Ikuto
    Kanematsu, Yuta
    Yoshida, Aki
    Saito, Kosuke
    Noguchi, Yoshihiro
    Ohno, Yuki
    Aoyama, Satoshi
    Yasuda, Masahiro
    Mizui, Takashi
    Yamamura, Masumi
    Teramachi, Hitomi
    FRONTIERS IN PHARMACOLOGY, 2017, 8
12345